EGFR mutation testing in non-small cell lung cancer

Sriram, K. B., Francis, S. M. Savarimuthu, Tan, M. E., Bowman, R. V., Yang, I. A. and Fong, K. M. (2010) EGFR mutation testing in non-small cell lung cancer. Current Respiratory Medicine Reviews, 6 4: 310-321. doi:10.2174/157339810793563776

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Sriram, K. B.
Francis, S. M. Savarimuthu
Tan, M. E.
Bowman, R. V.
Yang, I. A.
Fong, K. M.
Title EGFR mutation testing in non-small cell lung cancer
Journal name Current Respiratory Medicine Reviews   Check publisher's open access policy
ISSN 1573-398X
Publication date 2010-11-01
Sub-type Article (original research)
DOI 10.2174/157339810793563776
Open Access Status Not Open Access
Volume 6
Issue 4
Start page 310
End page 321
Total pages 12
Place of publication Bussum, Netherlands
Publisher Bentham Science Publishers
Language eng
Abstract Non-small cell lung cancer [NSCLC] is a major cause of cancer related deaths in the world. In a significant proportion of NSCLC cases, the Epidermal Growth Factor Receptor [EGFR] is over-expressed prompting the development of anti-EGFR therapies. Clinical studies of EGFR tyrosine kinase inhibitors [TKIs] demonstrated an overall response rate of 10% in NSCLC with higher response rates in females, never smokers, adenocarcinoma histology and East Asians. Mutations in exons 18-21 of the EGFR gene appear to be the most important molecular predictors of response to TKIs with response rates of >60% reported in most studies. Consequently screening NSCLC patients for tumours harbouring EGFR mutations will assist in selecting patients for TKI therapy. The gold standard for detecting EGFR mutations has been direct DNA sequencing however the sensitivity of this molecular technique is limited by the amount of tumour DNA is time and resource consuming. Recently several highly sensitive techniques have been developed to detect EGFR mutant DNA in different biological samples. In this review we aim to provide an overview of the clinical relevance of screening for EGFR mutations in NSCLC and recent molecular tests that have been developed for this purpose to allow the reader to critically evaluate the various methodologies that are available. © 2010 Bentham Science Publishers Ltd
Keyword EGFR
Molecular diagnosis
Non-small cell lung cancer
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2011 Collection
School of Medicine Publications
Version Filter Type
Citation counts: Scopus Citation Count Cited 1 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 15 Mar 2011, 19:15:23 EST by Lisa Hennell on behalf of School of Medicine